A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation is a phase 3 interventional study registered as NCT07566052, led by Astellas Pharma Global Development, and recruiting on the registry. Official title: A Randomised, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI). Planned enrolment is 356 participants (estimated). The study started in 2026-04-28 and primary completion is expected in 2030-06-30. No results have been posted on ClinicalTrials.gov.